Investor Relations Penumbra, Inc. [email protected] Source: Penumbra, Inc. Webcast & Conference Call Information Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more in ...

Toronto, Ontario--(Newsfile Corp. - July 2, 2024) - Peninsula Energy (ASX: PEN) is pleased to announce that the company is presenting a live virtual corporate update hosted by Red Cloud Financial Services on July 9th, 2024 at 2:00pm ET. About Peninsula Energy Peninsula Energy Wayne Heili +61893809920 info@pel.net.au The replay will be emailed out to all webinar registrants proceeding the event and will also be available on the Red Cloud website. About Red Cloud Financial Services Inc. www.redcloudfs.com www ...

PEN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. PEN has a Growth Style Score of A, forecasting year-over-year earnings growth of 37.3% for the current fiscal year. Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.02 to $2.87 per share. PEN also boasts an average earnings surprise of 26%. With a solid Zacks Rank and top-tier Growth and V ...

It has been about a month since the last earnings report for Penumbra (PEN) . Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Penumbra Q1 Earnings Miss, Margins Improve Penumbr ...

ALAMEDA, Calif., June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024. Event: Truist Securities MedTech Conference Date: Tuesday, June 18, 2024 Time: 10:05am ET/7:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the com ...

ALAMEDA, Calif., May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, June 6, 2024. Event: William Blair Growth Stock Conference Date: Thursday, June 6, 2024 Time: 12:20pm ET/9:20am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the c ...

Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - President, Chairman and CEO Maggie Yuen - CFO Jason Mills - Executive Vice President of Strategy Conference Call Participants Margaret Kaczor - William Blair Joanne Wuensch - Citi William Plovanic - Canaccord Genuity Fund Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Michael Sa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2024 Financial Results ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Total revenue increased to $278.7 million for the first quarter of 2024 compared to $241.4 million for the first quarter of 2023, an increase of 15.4%, or 15.2% in constant currency . The Uni ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2023 were $284.7 million, a year-over-year increase of 28.7% as reported and 27.9% on a constant currency basis [18] - For the full year 2023, total annual revenues were $1,058.5 million, representing growth of 25% as reported and 24.7% in constant currency over 2022 [18] - Non-GAAP operating income was $37.4 million, representing 13.1% of revenue, compared to $7.2 million or 3.3% of revenue for the same period last year [34] - Adjusted EBITDA reached $53.4 million or 18.8% of total revenue, compared to 10.5% in the fourth quarter last year [58] - Gross margin for Q4 2023 was 65.7%, up from 62.6% for Q4 2022 [55] Business Line Data and Key Metrics Changes - Global thrombectomy business achieved record revenue of $190.8 million in Q4 2023, growing 42.4% as reported and 41.6% in constant currency year-over-year [19] - U.S. thrombectomy business grew 46.4% compared to the same quarter a year ago, driven by growth in CAVT products [20] - Global embolization and access revenue was $93.9 million, representing an increase of 7.6% as reported and 6.7% in constant currency [19] - Revenue from vascular thrombectomy was $133.4 million, an increase of 64% year-over-year [30] Market Data and Key Metrics Changes - U.S. regions reported growth of 29.6%, primarily driven by 46.4% year-over-year growth in U.S. thrombectomy [29] - International regions increased 26.4% reported and 23.5% in constant currency [29] - The geographic mix of sales for Q4 2023 was 71.5% U.S. and 28.5% international [52] Company Strategy and Development Direction - The company is focused on three areas: innovation, internal readiness, and market access to enhance thrombectomy treatment [10] - Recent FDA clearance for Flash 2.0 is part of the strategy to expand the CAVT product line [12] - The company aims to leverage real-world data to validate the clinical benefits of CAVT and optimize treatment pathways [26] - The strategy includes expanding into international markets with regulatory and reimbursement efforts for CAVT products [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in expanding operating profitability in 2024, driven by significant opportunities in thrombectomy [9] - The company noted that 2023 was a watershed year for thrombectomy technology, with a growing recognition of its platform's capabilities [21] - Management highlighted the importance of collaboration with hospital systems to expand treatment pathways for thrombectomy patients [22] Other Important Information - The company ended Q4 2023 with cash, cash equivalents, and marketable securities of $289.2 million and no debt, an increase of $40.3 million from the previous quarter [60] - The company expects to continue positive operating cash flow trends in 2024 [60] Q&A Session Summary Question: Increased payer scrutiny on mechanical thrombectomy and ongoing profitability metrics - Management has not observed increased scrutiny on mechanical thrombectomy and noted positive trends in arterial procedures [42][43] Question: Sales cadence and growth expectations for 2024 - Management indicated that U.S. thrombectomy growth is expected to be strong at 27% to 30% year-over-year, with visibility into distributor order timing [69][71] Question: Discontinuation of products in certain countries - Management confirmed that some products will be discontinued in countries where reimbursement does not reflect product value, focusing on profitability [93] Question: Sales force hiring and ramp-up - Management reported successful hiring and training of new sales representatives, indicating confidence in meeting 2024 guidance [119]